FINCH 3: Phase III Trial of Filgotinib ± Methotrexate in Methotrexate-Naive Patients With Rheumatoid Arthritis

APLAR 2019: Brisbane, Australia; April 8-11, 2019; JCR: Kyoto, Japan; April 15-17, 2019
EULAR: Madrid, Spain; June 12-15, 2019
Addition of JAK1 inhibitor to methotrexate improved ACR20 responses compared with methotrexate alone in methotrexate-naive patients with RA.
Format: Microsoft PowerPoint (.ppt)
File Size: 209 KB
Released: June 27, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Lilly
Sanofi Genzyme and Regeneron Pharmaceuticals

Related Content

Expert commentary on key studies on safety and efficacy of JAK inhibitors from EULAR 2020 as reported by CCO

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: July 16, 2020 Expired: July 15, 2021

Expert commentary on key studies in RA prevention and treatment from EULAR 2020 as reported by CCO

Paul Emery, MA, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: July 16, 2020 Expired: July 15, 2021

From EULAR 2020, 52-week analysis of FINCH 1 trial of add-on filgotinib in rheumatoid arthritis with inadequate methotrexate response, by CCO

Released: July 13, 2020

From EULAR 2020, new safety analysis of upadacitinib use in patients with RA from 5 phase III SELECT trials

Released: July 7, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?